MNPR Company Profile and Key Details
Monopar Therapeutics Inc.
MNPR Stock Price Chart
Stock Price Today
Monopar Therapeutics Inc. (MNPR) stock surged +10.22%, trading at $48.00 on NASDAQ, up from the previous close of $43.55. The stock opened at $43.50, fluctuating between $41.83 and $49.98 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Company Information
| Employees | 9 |
| Beta | 1.1 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Monopar Therapeutics Inc. (NASDAQ: MNPR) stock price is $48.00 in the last trading session. During the trading session, MNPR stock reached the peak price of $49.98 while $41.83 was the lowest point it dropped to. The percentage change in MNPR stock occurred in the recent session was 10.22% while the dollar amount for the price change in MNPR stock was $4.45.
The NASDAQ listed MNPR is part of Biotechnology industry that operates in the broader Healthcare sector. Monopar Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Co-Founder, Chief Executive Officer, Pres & Director
Ms. Kim R. Tsuchimoto CPA
Chief Financial Officer, Sec., Treasurer & Director
Mr. Andrew J. Cittadine M.B.A.
Chief Operating Officer
Dr. Patrice P. Rioux M.D., Ph.D.
Acting Chief Medical Officer
MNPR's closing price is 3,006.8% higher than its 52-week low of $1.55 where as its distance from 52-week high of $49.98 is -3.96%.
Number of MNPR employees currently stands at 9.
Official Website of MNPR is: https://www.monopartx.com
MNPR could be contacted at phone 847 388 0349 and can also be accessed through its website. MNPR operates from 1000 Skokie Boulevard, Wilmette, IL 60091, United States.
MNPR stock volume for the day was 80.3K shares. The average number of MNPR shares traded daily for last 3 months was 90.3K.
The market value of MNPR currently stands at $292.92M with its latest stock price at $48.00 and 6.1M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com